Katarzyna M.
Bloch
*a,
Noreen
Yaqoob
a,
Andrew
Evans
a,
Robert
Radford
b,
Paul
Jennings
c,
Jan J. W. A
Boei
d,
Tara
McMorrow
b,
Craig
Slattery
b,
Michael P.
Ryan
b,
Hans
Gmuender
e,
Joost H. M.
van Delft
f and
Edward A.
Lock
a
aSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Byrom Street, Liverpool L3 3AF, UK. E-mail: K.Bloch@liv.ac.uk
bRenal Disease Research Group, School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Ireland
cDivision of Physiology, Department of Physiology and Medical Physics, Innsbruck Medical University, Innsbruck, Austria
dLeiden University Medical Centre, Department of Toxicogenetics, Leiden, The Netherlands
eGenedata AG, Basel, Switzerland
fDepartment of Health Risk Analyses and Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
First published on 4th September 2012
There is a need to develop quick, cheap, sensitive and specific methods to detect the carcinogenic potential of chemicals. Currently there is no in vitro model system for reliable detection of non-genotoxic carcinogens (NGTX) and current tests for detection of genotoxic carcinogens (GTX) can have low specificity. A transcriptomics approach holds promise and a few studies have utilised this technique. However, the majority of these studies have examined liver carcinogens with little work on renal carcinogens which may act via renal-specific NGTX mechanisms. In this study the normal rat renal cell line (NRK-52E) was exposed to sub-toxic concentrations of selected rat renal carcinogens and non-carcinogens (NC) for 6 h, 24 h and 72 h. Renal carcinogens were classified based on their presumed mode of action into GTX and NGTX classes. A whole-genome transcriptomics approach was used to determined genes and pathways as potential signatures for GTX, NGTX and those common to both carcinogenic events in vitro. For some of the GTX compounds an S9 drug metabolising system was included to aid pro-carcinogen activation. Only three genes were commonly deregulated after carcinogen (GTX + NGTX) exposure, one Mdm2 with a detection rate of 67%, and p21 and Cd55 with a detection rate of 56%. However, examination of enriched pathways showed that 3 out of 4 NGTX carcinogens and 4 out of 5 GTX carcinogens were related to known pathways involved in carcinogenesis giving a detection rate of 78%. In contrast, none of the NC chemicals induced any of the above genes or well-established carcinogenic pathways. Additionally, five genes (Lingo1, Hmox1, Ssu72, Lyrm and Usp9x) were commonly altered with 3 out of 4 NGTX carcinogens but not with NC or GTX carcinogens. However, there was no clear separation of GTX and NGTX carcinogens using pathway analysis with several pathways being common to both classes. The findings presented here indicate that the NRK-52E cell line has the potential to detect carcinogenic chemicals, although a much larger number of chemicals need to be used to confirm these findings.
The last 50 years of animal data suggests that carcinogenic compounds can be divided, based on their mode of action (MOA) into two classes, genotoxic (GTX) and non-genotoxic (NGTX).2 GTX carcinogens are readily detected using a number of short-term bacterial and cultured mammalian cell assays and although these assays are very sensitive, a problem of low specificity exists.3–5 NGTX carcinogens, however, are more problematic and depend in most cases on the outcome of a two-year rodent bioassay. Although some in vitro tests are available,6 currently there is no accurate in vitro model that can predict the carcinogenic potential of NGTX chemicals. Each year, several thousand new chemicals are entering the world markets and additionally under the Registration, Evaluation, Authorization and restriction of CHemicals (REACH) initiative there is a need to validate the toxicity of an estimated 68000 chemicals.7 High-throughput technologies such as whole-genome gene expression profiling have opened the way to understanding the systemic response to a toxic insult and also might speed up the process of risk assessment.8,9
In this study, the normal rat kidney epithelial cell line (NRK-52E) was exposed to eleven carcinogens and five non-carcinogens (NC) at their IC10 concentration at 72 h for 6 h, 24 h and 72 h. The selected renal carcinogens, all known to induce cancer in rats, were classified based on their presumed MOA into GTX, NGTX and NC classes.10 From the selected GTX compounds, two; aristolochic acid and benzo(a)pyrene have been classified by International Agency for Research on Cancer (IARC) as carcinogenic to human (Group 1). One, dimethylnitrosamine to Group 2A, probable human carcinogen, and three, 2-nitrofluorene, streptozotocin and potassium bromate to Group 2B, possible human carcinogen. The five NGTX carcinogens selected for this study are all chlorinated chemicals. Three of them, bromodichloromethane, chlorothalonil and ochratoxin A are classified as Group 2B while monuron is classified as Group 3, not carcinogenic to humans. S-(1,2-Dichlorovinyl)-L-cysteine is a non-classified metabolite of trichloroethylene (which itself belongs to Group 2A). As a control five NC, mainly widely used pharmaceuticals, clonidine, D-mannitol, diclofenac sodium, nifedipine and tolbutamide were used. Many GTX carcinogens undergo some degree of metabolism in order to interact with DNA.11,12 NRK-52E cells have poor cytochrome P450 drug metabolising capability13 (HPLC-MS/MS; Bloch, unpublished results), so additional studies were conducted with and without pre-incubation with rat liver β-naphthoflavone-induced S9 fraction. After 6 h, 24 h and 72 h of exposure the total RNA was isolated, purified, quality checked and whole-genome gene expression changes were determined using Affymetrix Rat GeneChip 230 2.0. In addition to alteration in transcriptome profile, DNA damage was determined by conducting the cytokinesis-blocked micronucleus assay.14
Statistical analysis was performed between the relevant control and test compound using a paired t-test (GraphPad InStat) with a p value <0.05 considered significant.
Class | Compound name and dose | % MN formationa |
---|---|---|
a Results are means ± SD with at least three different cell cultures per measurement. b Statistically significantly different from appropriate control, p < 0.05. c Statistically significantly different from appropriate control, P < 0.01. | ||
Control | DMSO | 0.26 ± 0.04 |
Medium | 0.27 ± 0.03 | |
S9 alone | 0.27 ± 0.15 | |
GTX | AA (1.65 μM) | 0.54 ± 0.11b |
BaP (40 μM) | 0.54 ± 0.04c | |
BaP (87 μM) | 1.40 ± 0.97 | |
BaP/S9 (87 μM) | 4.00 ± 0.70b | |
2NF (20 μM) | 0.18 ± 0.07 | |
2NF (70 μM) | 0.50 ± 0.35 | |
2NF/S9 (70 μM) | 0.90 ± 0.72 | |
KBrO3 (500 μM) | 6.63 ± 1.37b | |
NDMA (1 mM) | 0.32 ± 0.15 | |
STZ (350 μM) | 0.20 ± 0.10 | |
STZ/S9 (350 μM) | 0.80 ± 0.56 | |
NGTX | BDCM (0.47 mM) | 0.18 ± 0.10 |
CHL (1.1 μM) | 0.20 ± 0.20 | |
DCVC (3 μM) | 0.16 ± 0.16 | |
MON (250 μM) | 0.32 ± 0.34 | |
OTA (0.5 μM) | 0.23 ± 0.10 |
Class | Compound name and dose | Number of DEPs | Enriched KEGG pathways (P< 0.05) | ||
---|---|---|---|---|---|
6 h | 24 h | 72 h | |||
GTX | AA (1.65 μM) | 3 | 8 | 78 | p53 signalling (72 h), pathways in cancer (72 h), ubiquitin mediated proteolysis (72 h) |
BaP (40 μM) | 11 | 1 | 1 | — | |
KBrO3 (500 μM) | 1 | 8 | 57 | — | |
2NF (20 μM) | 6 | 0 | 0 | — | |
NDMA (1 mM) | 10 | 0 | 21 | — | |
STZ (350 μM) | — | — | 9 | — | |
NGTX | BDCM (0.47 mM) | 0 | 0 | 2 | — |
CHL (1.1 μM) | 174 | 324 | 317 | MAPK signalling (6 h), Toll-like receptor signalling (6 h), cell cycle (6 h), Steroid biosynthesis (24 h), biosynthesis of unsaturated fatty acids (24 h), proteasome assembly (24 h), terpenoid backbone biosynthesis (24 h), focal adhesion (72 h), ubiquitin mediated proteolysis (72 h), pathways in cancer (72 h) | |
DCVC (3 μM) | 0 | 1 | 1448 | Aminoacyl-tRNA biosynthesis (72 h), cell cycle (72 h), ubiquitin mediated proteolysis (72 h), regulation of actin cytoskeleton (72 h), endocytosis (72 h), pyrimidine metabolism (72 h), pathways in cancer (72 h), protein export (72 h), spliceosome (72 h), focal adhesion (72 h), p53 signalling (72 h), valine, leucine and isoleucine biosynthesis (72 h), mTOR signalling pathway (72 h) | |
MON (250 μM) | 6 | 24 | 123 | Mevalonate kinase pathway (6 h) | |
OTA (0.5 μM) | 170 | 1057 | 723 | Pyrimidine metabolism (24 h and 72 h), purine metabolism (24 h), cell cycle (24 h), WNT-signalling (24 h), p53 signalling (24 h), spliceosome (24 h), steroid biosynthesis (24 h), fructose and mannose metabolism (24 h), pathways in cancer (24 h), renal cell carcinoma (24 h), sphingolipid metabolism(72 h), lysosome (72 h) | |
NC | CLO (1.12 mM) | 42 | 16 | 46 | Steroid biosynthesis (6 h) |
DS (16 μM) | 7 | 1 | 22 | — | |
MAN (10 mM) | 1 | 2 | 94 | Focal adhesion (72 h) | |
NIF (35 μM) | 4 | 1 | 0 | — | |
TOL (0.37 mM) | 0 | 4 | 31 | Tight junction (72 h) |
Entrez gene ID | Gene | Deregulation after exposure |
---|---|---|
314856 | Mdm2 | AA (72 h), BaP/S9 (72 h), 2NF/S9 (72 h), STZ/S9 (72 h), CHL (24 h), DCVC (72 h) |
114851 | p21 | AA (72 h), KBrO3 (24 h), BaP/S9 (72 h), 2NF/S9 (72 h),OTA (24 h) |
64036 | Cd55 | KBrO3 (72 h), BaP/S9 (72 h), 2NF/S9 (72 h), STZ/S9 (72 h), OTA(72 h) |
25240 | Aqp1 | AA (72 h), BaP/S9 (72 h), DCVC (72 h), OTA (72 h) |
Three NGTX carcinogens affected cell cycle pathways, at different time points CHL, 6 h; OTA, 24 h and DCVC 72 h, with common deregulation of genes from the GADD45 family (growth arrest and DNA-damage-inducible). Intriguingly, both CHL and DCVC up-regulated Gadd45 genes whereas OTA exposure down-regulated them. Additionally, three genes were commonly altered after DCVC and OTA exposure these were, Mad2l2 (MAD2 mitotic arrest deficient-like2), Rad21 (RAD21 homolog, S. pombe) and Rbx1 (Ring-box 1). Mad2l2 is a component of the mitotic spindle assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate. Interestingly, Mad2l2 and Rad21 were up-regulated and Rbx1 down-regulated after DCVC exposure, while with OTA, Mad2l2 and Rad21 were down-regulated and Rbx1 was up-regulated. In addition to the cell cycle pathway, CHL (72 h), DCVC (72 h) and OTA (24 h) exposure also significantly enriched cancer pathways, with three genes commonly deregulated from the Frizzled and Integrin family and Tcf (similar to transcription factor 7-like 2, T-cell specific). The canonical p53 signalling pathway was also enriched after 72 h exposure to DCVC and 24 h exposure to OTA, with two commonly altered genes, Rrm2 (ribonucleotide reductase M2) and Gadd45. CHL and DCVC enriched the focal adhesion pathway with two commonly deregulated genes; Pak1 (p21 protein (Cdc42/Rac)-activated kinase 1) and Akt3 (V-akt murine thymoma viral oncogene homolog 3). Genes from the Integrin and Laminin family were also commonly deregulated by CHL and DCVC.
In addition, OTA (24 h) enriched WNT-signalling and the renal cell carcinoma pathway, while DCVC (72 h) altered the mTOR pathway and CHL (6 h) enriched the MAPK signalling pathway (Table 2). MON did not alter any canonical cancer pathways, but down-regulated the mevalonate kinase pathway (Table 2).
AA was the only compound (from the GTX without S9) that enriched cancer related pathways (Table 2). BaP and 2NF had a very small effect on the transcriptome profile, whereas exposure to KBrO3 altered 66 genes over 72 h (Table 2). As BaP and 2NF are known pro-carcinogen's that need to be metabolized to DNA reactive proximate carcinogens to exert their carcinogenic potential, an external metabolic activation system, β-naphthoflavone-induced rat liver S9 was used. Exposure of NRK-52E cells to S9 alone altered genes involved mainly with immunological functions: NOD-like receptor and chemokine signalling suggestive of an immune response. No genes involved in cancer-related pathway were altered in the presence of S9 alone. AA was not studied in the presence of S9 as nitro-reduction is primarily involved in the activation while oxidation via CYP1A1 has been shown to protect against the carcinogenic effect of AA.20 In general, exposure to GTX compounds (BaP, 2NF and STZ) together with induced S9 increased the number of DEPs and helped to predict their carcinogenic potential of the compounds (Table 5).
Compound name and dose | Number of DEPs | Enriched KEGG pathways (P< 0.05) |
---|---|---|
BaP (87 μM) | 1 | — |
BaP/S9 (87 μM) | 93 | MAPK signalling, focal adhesion, pathways in cancer |
2NF (70 μM) | 87 | p53 signalling pathway |
2NF/S9 (70 μM) | 110 | p53 signalling, aminoacyl-tRNA biosynthesis, porphyrin metabolism, glycine, serine and threonine metabolism, cell cycle |
STZ (350 μM) | 9 | — |
STZ/S9 (350 μM) | 58 | p53 signalling pathway |
Five genes with the same pattern of expression were found to be commonly deregulated by BaP, 2NF and STZ after prior external metabolic activation; Mgmt (O-6-methylguanine-DNA methyltransferase), Epoh1 (epoxide hydrolase 1), Scarb2 (scavenger receptor class B, member 2), Jam3 (junctional adhesion molecule 3) and Cd55 (Table 6). However, from these five deregulated genes, three were also deregulated by NGTX carcinogens. Cd55, in addition to being down-regulated by BaP, STZ and 2NF after metabolic pre-incubation, was also down-regulated by KBrO3 and by the NGTX carcinogen OTA, whereas Mgmt and Scarb2 were up-regulated by DCVC exposure. Thus it is much more difficult to find a set of specific genes deregulated by the GTX carcinogens.
In addition, no commonly deregulated genes were found to be altered by GTX carcinogens exposure, that were positive for MN induction (AA, KBrO3 and BaP/S9) after 72 h exposure.
In this work eleven chemicals that cause renal tubule tumours in rats have been evaluated. Six of them have previously been shown to act via a GTX mechanism and five chemicals are thought to act by a NGTX mechanism.10 Additionally five NC had been used as controls. Cytotoxicity studies were conducted using all 16 chemicals on NRK-52E cells, to assess the effect that these chemicals had on the cells. Determination of cytotoxicity is an initial step toward the characterisation of chemicals. Although cytotoxicity assays per se does not provide mechanistic data, they shed light on cell response/susceptibility to investigated cytotoxins. Furthermore, knowledge of the concentration range that induces cytotoxicity enables better definition of concentrations to be employed in in-depth descriptive and mechanistic studies such as gene expression profiling. As the main aim of the project was to try to detect an early carcinogenic potential of the selected compounds, the endpoint of interest was carcinogenicity not cytotoxicity, the selected dose that cause only 10% cytotoxicity (IC10) and thus have small but visible effect on the cell line was used. For transcriptomics, only one dose was investigated, but with different times of exposure. The reason for this being the analysis of previous published studies, showing that in in vitro models, treatment time has a much larger impact on gene expression than the chemical's dose.21,22 Three time points were selected to provide additional data 6 h, 24 h and 72 h. The early exposure time point (6 h) was selected as GTX chemicals have been shown to induce DNA damage and repair in a matter of few hours after administration.23,24 As the main aim of this study was to look at the carcinogenicity of the chemical and 1/3 of the chemicals used are known to be DNA-reactive, the in vitro micronucleus assay was used to assess if the dose used (IC10) had any effect on DNA. The assay confirmed the lack of clastogenicity with NGTX chemicals (Table 1). In the GTX group, chromosomal damage was proven for KBrO3, AA and BaP. The clastogenicity after KBrO3 exposure is believed to be due to oxidative stress, increased reactive oxygen species, glutathione depletion25 and 8-OHdG formation leading to double strand breaks in the DNA.26,27 AA has also been shown to increase MN formation in mouse bone marrow cells,28 human lymphocytes exposed to the plant extract from Aristolochia29 and HepG2 cells.30 A small, but statistically significant, induction of MN was seen with BaP (Table 1). BaP is known to require metabolism by cytochrome P450 to undergo metabolic activation31 and as NRK-52E cells do not possess functional cytochrome P450 (as quantified by HPLC-MS/MS with a range of different substrates, Bloch, unpublished results) this finding was unexpected, but may be explained by photoactivation of the chemical.32 A statistically significant increase in MN formation was observed after the addition of a xenobiotic drug metabolising system in case of BaP and a small but not statistically significant increase was noted after 2NF/S9 and STZ/S9 (Table 1).
Interestingly Aqp1 was also altered by GTX and NGTX carcinogens and recently Aqp1 has been proposed as a renal cancer biomarker.35
Additionally examination of pathways enriched by chemical exposure, showed that 3 out of 4 (75%) NGTX carcinogens and 4 out of 5 (80%) GTX carcinogens (AA, BaP/S9, 2NF/S9, STZ/S9, with KBrO3 being the only chemical that did not enriched any pathway) were related to known pathways involved in carcinogenesis. In contrast, none of the NC chemicals induce any of the well-established carcinogenic pathways. Mannitol and BaP/S9 both enriched the focal adhesion pathway, however there was only one common gene Col1a1. So far gene expression profiling studies using cancer related pathways has shown a detection rate of 78% for renal carcinogens (7/9) under the conditions of these studies.
The enriched pathways that were affected by two or more carcinogens include; p53 signalling pathway (AA, 2NF/S9, STZ/S9, DCVC and OTA), pathways in cancer (AA, BaP/S9, CHL, DCVC and OTA), cell cycle (2NF/S9, DCVC and OTA), focal adhesion (BaP/S9, CHL and DCVC), MAPK signalling pathway (BaP/S9 and CHL). Thus, this study has shown that NRK-52E, rat renal cell model has a potential for detecting renal carcinogens in vitro. MON was the only NGTX compound that did not alter any canonical cancer related pathways. However, using a less stringent p value of <0.01 MON increased pathways in cancer, renal cell carcinoma and the cell cycle 72 h after exposure.
As mentioned above there is a real problem of early detection of NGTX carcinogens. In NRK-52E cells, exposure to three of the four compounds (except for MON) commonly deregulated five genes, Lingo1, Hmox1, Ssu72, Lyrm1 and Usp9x (Table 4).36Lingo1 is currently implicated in oligodentrocyte differentiation and axonal myelination and no study so far have shown its involvement in carcinogenesis. HMOX1 which is under the regulation of Nrf2, plays an important role in oxidative injury37 and has been shown to regulate cell proliferation, modulate inflammatory response and facilitate angiogenesis.38Ssu72 encodes a protein involved in RNA processing and termination. Little is known about the function of LYRM1, although Qiu et al.39 has shown that the protein is involved in modulation of cell growth and apoptosis in pre-adipocytes. USP9X is a member of the peptidase family that regulate the production and recycling of ubiquitin which are involved in the control of cell growth, differentiation and apoptosis.40 Recently Pérez-Mancera et al.41 proposed that USP9X might be a major tumour suppressor gene, with prognostic and therapeutic relevance in pancreatic ductal adenocarcinoma. NGTX carcinogens predominantly up-regulated genes involving in signalling pathways, whereas genes involved in metabolism were predominantly down-regulated.
This finding agrees with studies analysing gene expression in human clear cell renal carcinoma, where loss of normal renal function, down-regulation of metabolic genes and alteration in multiple canonical cancer-associated pathways occurs, including cell cycle, focal adhesion, ECM-interaction and disruption in amino-acid metabolism.42,43 Additionally as mentioned above three NGTX carcinogens commonly deregulated the cell cycle pathway with common deregulation of genes from the GADD45 family. Proteins encoded by these genes are DNA-damaging sensor proteins, with up regulation of expression after a DNA-damaging event. They interact with both CDK1 (cyclin-dependent kinase 1) and CCNB1 (cyclin B1), resulting in inhibition of the kinase activity of the CDK1/CCNB1 complex, and function as a negative growth control. In addition, all three NGTX deregulated different cancer pathways such as WNT-signalling, renal cell carcinoma pathway, mTOR pathway and MAPK signalling pathway (Table 2).
GTX compounds, except from AA, without prior metabolic activation altered a much smaller number of genes as compared to NGTX compounds and did not alter cancer related pathways. Thus an external metabolising system was used to improve the metabolic capabilities of the NRK-52E cells. Pre-incubation with an induced rat liver S9 fraction, which itself did not altered any cancer related pathways, was shown to improve the detection of carcinogenic potential of GTX compounds (Table 5). Following BaP/S9, 2NF/S9 and STZ/S9 exposure five genes were found to be commonly deregulated; Mgmt, Scarb2, Epoh1, Jam3 and Cd55 (Table 6). Mgmt encodes an enzyme that repairs alkylated guanine in DNA. STZ is a known alkylating agent, while BaP and 2NF are not, however Ellinger-Ziegelbauer and coworkers reported an increase in Mgmt after in vivo exposure to 2NF and other GTX compounds.44 While Grombacher and coworkers showed that p53 regulates Mgmt expression and that Mgmt is induced after GTX stress, being one of the first DNA repair gene to be up-regulated.45Epoh1 is a critical enzyme in xenobiotic detoxification, which catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols. However, EPOH1 has been shown to activate BaP to mutagenic and carcinogenic products and Epoh1 polymorphisms have been associated with the onset of numerous cancers.46–48Scarb2 encodes a transmembrane glycoprotein that is located in lysosome and endosome membranes and may participate in membrane transportation and the reorganization of endosomal/lysosomal compartments. Huang and coworkers reported the loss of heterozygosity in Scarb2 in human hepatocellular carcinoma.49Jam3 encodes a protein that is expressed in close proximity to tight junctions of polarized endothelial and epithelial cells and also mediates cell adhesive events between tumour cells and the endothelium.50
In addition, cancer-related pathways were also enriched with induction of the p53 signalling pathway after STZ/S9 and 2NF/S9 exposure and MAPK signalling after BaP/S9 exposure. Enrichment of MAPK signalling pathway after BaP exposure has also been reported by others.51–53 MAPK signalling pathway was also enriched after 6 h exposure to CHL (NGTX), although only one gene Gadd153 was commonly up-regulated by both compounds. Although the addition of the S9 fraction greatly improved the response to BaP and STZ, with 2NF/S9 the results were more ambiguous. 2NF (40 μM) alone altered 6 genes over 72 h, however increasing the dose to 70 μM led to 87 genes being altered while the addition of S9 to 2NF (70 μM) led to 110 genes being altered. This suggests in the case of 2NF that the dose was more important than metabolic pre-incubation. However, closer examination revealed that although the higher concentration induced more DEPs, the DE genes altered after exposure to 2NF alone were involved in apoptosis in contrast to 2NF/S9 exposure where the genes were primarily involved in metabolism (amino acid transport, amino acid activation and cholesterol biosynthesis).
In addition, there were some similarities after exposure to 2NF (70 μM) with and without S9; ten commonly deregulated genes associated with cancer and a significant enrichment of the p53 signalling pathway. In addition, exposure to 2NF/S9 enriched four pathways namely aminoacyl-tRNA biosynthesis, glycine, serine and threonine metabolism and porphyrin metabolism, all being down-regulated (Table 5).
KEGG pathway | No. of genes involved in the pathway | P-value |
---|---|---|
p53 signalling pathway | 9 | 4.1 × 10−5 |
Pathways in cancer | 17 | 4.6 × 10−4 |
Small cell lung cancer | 7 | 5.8 × 10−3 |
ErbB signalling pathway | 7 | 6.6 × 10−3 |
Melanoma | 6 | 1.2 × 10−2 |
Cell cycle | 8 | 1.2 × 10−2 |
MAPK signalling pathway | 12 | 1.6 × 10−2 |
Glycine, serine and threonine metabolism | 4 | 2.5 × 10−2 |
Terpenoid backbone biosynthesis | 3 | 3.0 × 10−2 |
Ubiquitin mediated proteolysis | 7 | 3.9 × 10−2 |
Aminoacyl-tRNA biosynthesis | 4 | 4.4 × 10−2 |
KEGG pathway | No. of genes involved in the pathway | P-value |
---|---|---|
Cell cycle | 41 | 7.2 × 10−8 |
Steroid biosynthesis | 11 | 1.5 × 10−5 |
Aminoacyl-tRNA biosynthesis | 17 | 2.7 × 10−5 |
Spliceosome | 34 | 3.8 × 10−5 |
Pyrimidine metabolism | 27 | 1.3 × 10−4 |
p53 signalling pathway | 21 | 2.8 × 10−4 |
Terpenoid backbone biosynthesis | 8 | 1.1 × 10−3 |
Ubiquitin mediated proteolysis | 30 | 2.2 × 10−3 |
Sphingolipid metabolism | 13 | 7.7 × 10−3 |
Pathways in cancer | 58 | 1.2 × 10−2 |
RNA polymerase | 9 | 1.8 × 10−2 |
Porphyrin metabolism | 10 | 1.8 × 10−2 |
Fatty acid metabolism | 12 | 2.0 × 10−2 |
Glycine, serine and threonine metabolism | 10 | 2.2 × 10−2 |
Protein export | 5 | 2.4 × 10−2 |
Amino and nucleotide sugar metabolism | 12 | 2.4 × 10−2 |
Small cell lung cancer | 19 | 2.6 × 10−2 |
RNA degradation | 14 | 3.7 × 10−2 |
DNA replication | 10 | 3.8 × 10−2 |
Renal cell carcinoma | 16 | 3.9 × 10−2 |
Colorectal cancer | 18 | 4.0 × 10−2 |
Focal adhesion | 36 | 4.4 × 10−2 |
Arginine and proline metabolism | 13 | 4.6 × 10−2 |
Regulation of actin cytoskeleton | 38 | 4.7 × 10−2 |
WNT signalling pathway | 28 | 4.8 × 10−2 |
In summary, we have been able to detect renal carcinogens using pathway analysis with a success rate of 78% for 9 carcinogens, using an S9 drug metabolising system for the GTX compounds. In addition we could clearly separate these carcinogens from 5 NC. With regard to separating GTX from NGTX carcinogens we identified several common pathways for both classes, making it difficult to separate direct acting carcinogens from the indirect acting carcinogens.
This journal is © The Royal Society of Chemistry 2012 |